Predicting relapse in schizophrenia: Is BDNF a plausible biological marker?

Anilkumar R Pillai, Nina R. Schooler, Diya Peter, Stephen Warwick Looney, Donald C. Goff, Alexander Kopelowicz, John Lauriello, Theo Manschreck, Alan Mendelowitz, Del D. Miller, Joanne B. Severe, Daniel R. Wilson, Donna Ames, Juan Bustillo, John M. Kane, Peter F Buckley

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Understanding the biological processes that underlie why patients relapse is an issue of fundamental importance to the detection and prevention of relapse in schizophrenia. Brain Derived Neurotrophic Factor (BDNF), a facilitator of brain plasticity, is reduced in patients with schizophrenia. In the present study, we examined whether decreases in plasma BDNF levels could be used as a biological predictor of relapse in schizophrenia. A total of 221 patients were prospectively evaluated for relapse over 30 months in the Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared to Injectables: eValuating Efficacy (PROACTIVE) study. Serial blood samples were collected at a maximum of 23 time points during the 30-month trial and BDNF levels were measured in plasma samples by ELISA. Receiver Operating Characteristic (ROC) curve analysis indicated that BDNF was not a significant predictor of relapse, hospitalization or exacerbation. Regardless of treatment group (oral second generation antipsychotic vs. long-acting injectable risperidone microspheres), baseline BDNF value did not differ significantly between those who experienced any of the adverse outcomes and those who did not. While contrary to the study hypothesis, these robust results offer little support for the use of plasma BDNF alone as a biomarker to predict relapse in schizophrenia.

Original languageEnglish (US)
Pages (from-to)263-268
Number of pages6
JournalSchizophrenia Research
Volume193
DOIs
StatePublished - Mar 1 2018

Fingerprint

Brain-Derived Neurotrophic Factor
Schizophrenia
Biomarkers
Recurrence
Antipsychotic Agents
Biological Phenomena
Injections
Risperidone
Secondary Prevention
Microspheres
ROC Curve
Hospitalization
Enzyme-Linked Immunosorbent Assay
Brain

Keywords

  • BDNF
  • Clinical trial
  • Relapse
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Predicting relapse in schizophrenia : Is BDNF a plausible biological marker? / Pillai, Anilkumar R; Schooler, Nina R.; Peter, Diya; Looney, Stephen Warwick; Goff, Donald C.; Kopelowicz, Alexander; Lauriello, John; Manschreck, Theo; Mendelowitz, Alan; Miller, Del D.; Severe, Joanne B.; Wilson, Daniel R.; Ames, Donna; Bustillo, Juan; Kane, John M.; Buckley, Peter F.

In: Schizophrenia Research, Vol. 193, 01.03.2018, p. 263-268.

Research output: Contribution to journalArticle

Pillai, AR, Schooler, NR, Peter, D, Looney, SW, Goff, DC, Kopelowicz, A, Lauriello, J, Manschreck, T, Mendelowitz, A, Miller, DD, Severe, JB, Wilson, DR, Ames, D, Bustillo, J, Kane, JM & Buckley, PF 2018, 'Predicting relapse in schizophrenia: Is BDNF a plausible biological marker?', Schizophrenia Research, vol. 193, pp. 263-268. https://doi.org/10.1016/j.schres.2017.06.059
Pillai, Anilkumar R ; Schooler, Nina R. ; Peter, Diya ; Looney, Stephen Warwick ; Goff, Donald C. ; Kopelowicz, Alexander ; Lauriello, John ; Manschreck, Theo ; Mendelowitz, Alan ; Miller, Del D. ; Severe, Joanne B. ; Wilson, Daniel R. ; Ames, Donna ; Bustillo, Juan ; Kane, John M. ; Buckley, Peter F. / Predicting relapse in schizophrenia : Is BDNF a plausible biological marker?. In: Schizophrenia Research. 2018 ; Vol. 193. pp. 263-268.
@article{7d953a8c41ca47d3a50a5afb0891ea5a,
title = "Predicting relapse in schizophrenia: Is BDNF a plausible biological marker?",
abstract = "Understanding the biological processes that underlie why patients relapse is an issue of fundamental importance to the detection and prevention of relapse in schizophrenia. Brain Derived Neurotrophic Factor (BDNF), a facilitator of brain plasticity, is reduced in patients with schizophrenia. In the present study, we examined whether decreases in plasma BDNF levels could be used as a biological predictor of relapse in schizophrenia. A total of 221 patients were prospectively evaluated for relapse over 30 months in the Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared to Injectables: eValuating Efficacy (PROACTIVE) study. Serial blood samples were collected at a maximum of 23 time points during the 30-month trial and BDNF levels were measured in plasma samples by ELISA. Receiver Operating Characteristic (ROC) curve analysis indicated that BDNF was not a significant predictor of relapse, hospitalization or exacerbation. Regardless of treatment group (oral second generation antipsychotic vs. long-acting injectable risperidone microspheres), baseline BDNF value did not differ significantly between those who experienced any of the adverse outcomes and those who did not. While contrary to the study hypothesis, these robust results offer little support for the use of plasma BDNF alone as a biomarker to predict relapse in schizophrenia.",
keywords = "BDNF, Clinical trial, Relapse, Schizophrenia",
author = "Pillai, {Anilkumar R} and Schooler, {Nina R.} and Diya Peter and Looney, {Stephen Warwick} and Goff, {Donald C.} and Alexander Kopelowicz and John Lauriello and Theo Manschreck and Alan Mendelowitz and Miller, {Del D.} and Severe, {Joanne B.} and Wilson, {Daniel R.} and Donna Ames and Juan Bustillo and Kane, {John M.} and Buckley, {Peter F}",
year = "2018",
month = "3",
day = "1",
doi = "10.1016/j.schres.2017.06.059",
language = "English (US)",
volume = "193",
pages = "263--268",
journal = "Schizophrenia Research",
issn = "0920-9964",
publisher = "Elsevier",

}

TY - JOUR

T1 - Predicting relapse in schizophrenia

T2 - Is BDNF a plausible biological marker?

AU - Pillai, Anilkumar R

AU - Schooler, Nina R.

AU - Peter, Diya

AU - Looney, Stephen Warwick

AU - Goff, Donald C.

AU - Kopelowicz, Alexander

AU - Lauriello, John

AU - Manschreck, Theo

AU - Mendelowitz, Alan

AU - Miller, Del D.

AU - Severe, Joanne B.

AU - Wilson, Daniel R.

AU - Ames, Donna

AU - Bustillo, Juan

AU - Kane, John M.

AU - Buckley, Peter F

PY - 2018/3/1

Y1 - 2018/3/1

N2 - Understanding the biological processes that underlie why patients relapse is an issue of fundamental importance to the detection and prevention of relapse in schizophrenia. Brain Derived Neurotrophic Factor (BDNF), a facilitator of brain plasticity, is reduced in patients with schizophrenia. In the present study, we examined whether decreases in plasma BDNF levels could be used as a biological predictor of relapse in schizophrenia. A total of 221 patients were prospectively evaluated for relapse over 30 months in the Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared to Injectables: eValuating Efficacy (PROACTIVE) study. Serial blood samples were collected at a maximum of 23 time points during the 30-month trial and BDNF levels were measured in plasma samples by ELISA. Receiver Operating Characteristic (ROC) curve analysis indicated that BDNF was not a significant predictor of relapse, hospitalization or exacerbation. Regardless of treatment group (oral second generation antipsychotic vs. long-acting injectable risperidone microspheres), baseline BDNF value did not differ significantly between those who experienced any of the adverse outcomes and those who did not. While contrary to the study hypothesis, these robust results offer little support for the use of plasma BDNF alone as a biomarker to predict relapse in schizophrenia.

AB - Understanding the biological processes that underlie why patients relapse is an issue of fundamental importance to the detection and prevention of relapse in schizophrenia. Brain Derived Neurotrophic Factor (BDNF), a facilitator of brain plasticity, is reduced in patients with schizophrenia. In the present study, we examined whether decreases in plasma BDNF levels could be used as a biological predictor of relapse in schizophrenia. A total of 221 patients were prospectively evaluated for relapse over 30 months in the Preventing Relapse in Schizophrenia: Oral Antipsychotics Compared to Injectables: eValuating Efficacy (PROACTIVE) study. Serial blood samples were collected at a maximum of 23 time points during the 30-month trial and BDNF levels were measured in plasma samples by ELISA. Receiver Operating Characteristic (ROC) curve analysis indicated that BDNF was not a significant predictor of relapse, hospitalization or exacerbation. Regardless of treatment group (oral second generation antipsychotic vs. long-acting injectable risperidone microspheres), baseline BDNF value did not differ significantly between those who experienced any of the adverse outcomes and those who did not. While contrary to the study hypothesis, these robust results offer little support for the use of plasma BDNF alone as a biomarker to predict relapse in schizophrenia.

KW - BDNF

KW - Clinical trial

KW - Relapse

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=85025432898&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025432898&partnerID=8YFLogxK

U2 - 10.1016/j.schres.2017.06.059

DO - 10.1016/j.schres.2017.06.059

M3 - Article

C2 - 28734907

AN - SCOPUS:85025432898

VL - 193

SP - 263

EP - 268

JO - Schizophrenia Research

JF - Schizophrenia Research

SN - 0920-9964

ER -